140 related articles for article (PubMed ID: 9402310)
1. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.
Stehle G; Wunder A; Sinn H; Schrenk HH; Schütt S; Frei E; Hartung G; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Oct; 8(9):835-44. PubMed ID: 9402310
[TBL] [Abstract][Full Text] [Related]
2. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Stehle G; Sinn H; Wunder A; Schrenk HH; Schütt S; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Aug; 8(7):677-85. PubMed ID: 9311444
[TBL] [Abstract][Full Text] [Related]
3. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.
Wunder A; Stehle G; Schrenk HH; Hartung G; Heene DL; Maier-Borst W; Sinn H
Int J Cancer; 1998 Jun; 76(6):884-90. PubMed ID: 9626357
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats.
Kremer P; Hartung G; Bauder-Wüst U; Schrenk HH; Wunder A; Heckl S; Zillmann U; Sinn H
Anticancer Drugs; 2002 Jul; 13(6):615-23. PubMed ID: 12172507
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Apr; 10(4):405-11. PubMed ID: 10378676
[TBL] [Abstract][Full Text] [Related]
7. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
Han JH; Oh YK; Kim DS; Kim CK
Int J Pharm; 1999 Oct; 188(1):39-47. PubMed ID: 10528081
[TBL] [Abstract][Full Text] [Related]
8. Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosylated albumins.
Han J; Lim SJ; Lee MK; Kim CK
Drug Deliv; 2001; 8(3):125-34. PubMed ID: 11570592
[TBL] [Abstract][Full Text] [Related]
9. Imaging tumor folate receptors using 111In-DTPA-methotrexate.
Ilgan S; Yang DJ; Higuchi T; Zareneyrizi F; Kim EE; Podoloff DA
Cancer Biother Radiopharm; 1998 Jun; 13(3):177-84. PubMed ID: 10850353
[TBL] [Abstract][Full Text] [Related]
10. A novel methotrexate-albumin (mtx-rsa)-conjugate causes significant growth delay of o-342 ovarian-carcinoma in-vivo.
Steinmann A; Friedrich E; Rath U
Oncol Rep; 1995 Jan; 2(1):107-9. PubMed ID: 21597699
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate in solid tumors.
Jain RK; Wei J; Gullino PM
J Pharmacokinet Biopharm; 1979 Apr; 7(2):181-94. PubMed ID: 20218013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
13. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
Yuan SH; Ge WH; Huo J; Wang XH
Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
[TBL] [Abstract][Full Text] [Related]
14. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies.
Schilling U; Friedrich EA; Sinn H; Schrenk HH; Clorius JH; Maier-Borst W
Int J Rad Appl Instrum B; 1992 Aug; 19(6):685-95. PubMed ID: 1522023
[TBL] [Abstract][Full Text] [Related]
15. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats.
Kim CK; Han JH
J Microencapsul; 1995; 12(4):437-46. PubMed ID: 8583318
[TBL] [Abstract][Full Text] [Related]
17. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
18. Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system.
Hawkins GA; McCabe RP; Kim CH; Subramanian R; Bredehorst R; McCullers GA; Vogel CW; Hanna MG; Pomato N
Cancer Res; 1993 May; 53(10 Suppl):2368-73. PubMed ID: 8485723
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
20. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.
Wunder A; Müller-Ladner U; Stelzer EH; Funk J; Neumann E; Stehle G; Pap T; Sinn H; Gay S; Fiehn C
J Immunol; 2003 May; 170(9):4793-801. PubMed ID: 12707361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
